| Alexei Viazmenski, MD | |
|
1 Medical Center Dr, Lebanon, NH 03756-1000 | |
| (603) 650-5000 | |
| Not Available |
| Full Name | Alexei Viazmenski |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 23 Years |
| Location | 1 Medical Center Dr, Lebanon, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386730646 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 14782 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mary Hitchcock Memorial Hospital | Lebanon, NH | Hospital |
| Alice Peck Day Memorial Hospital | Lebanon, NH | Hospital |
| Cottage Hospital | Woodsville, NH | Hospital |
| Huggins Hospital | Wolfeboro, NH | Hospital |
| Springfield Hospital | Springfield, VT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cottage Hospital | 1951219617 | 25 |
| Dartmouth-hitchcock Clinic | 4183537509 | 1139 |
News Archive
The FRS Company, a developer and distributor of FRS® Healthy Energy® products, announced today that it has received $23.1 million in its latest financing round led by Oak Investment Partners, LLC. Oak Investment Partners was an early investor in The FRS Company, and its continued support of FRS validates the company's aggressive business strategy for national and international expansion and explosive sales growth.
Despite technological advances, discrimination against consumers inhibited by disabilities or disadvantaged by personal circumstances remains a significant problem. Many people today find themselves excluded by mainstream, day-to-day services on which they rely, such as banks, utilities, telecoms, health services and local authority providers. Their vulnerability can be hidden, a consequence of personal trauma or a health condition, or temporary resulting from a job loss. These are complex issues for organizations to identify and respond to appropriately.
Stem cell biology takes another exciting leap forward as scientists report that normal tissue cells can be reprogrammed to exhibit many of the properties that are characteristic of embryonic stem cells, including the ability to give rise to multiple cell types and contribute to the germline.
ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced results from the trastuzumab emtansine Phase III EMILIA trial conducted by Roche.
Obesity − as research in the past decade has shown − is first and foremost a brain disease. Researchers at Helmholtz Zentrum München, partners in the German Center for Diabetes Research, have now discovered a molecular switch that controls the function of satiety neurons and therefore body weight. The findings were published in the journal 'Nature Metabolism'.
› Verified 4 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386697803 PECOS PAC ID: 4183537509 Enrollment ID: O20031111000313 |
News Archive
The FRS Company, a developer and distributor of FRS® Healthy Energy® products, announced today that it has received $23.1 million in its latest financing round led by Oak Investment Partners, LLC. Oak Investment Partners was an early investor in The FRS Company, and its continued support of FRS validates the company's aggressive business strategy for national and international expansion and explosive sales growth.
Despite technological advances, discrimination against consumers inhibited by disabilities or disadvantaged by personal circumstances remains a significant problem. Many people today find themselves excluded by mainstream, day-to-day services on which they rely, such as banks, utilities, telecoms, health services and local authority providers. Their vulnerability can be hidden, a consequence of personal trauma or a health condition, or temporary resulting from a job loss. These are complex issues for organizations to identify and respond to appropriately.
Stem cell biology takes another exciting leap forward as scientists report that normal tissue cells can be reprogrammed to exhibit many of the properties that are characteristic of embryonic stem cells, including the ability to give rise to multiple cell types and contribute to the germline.
ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced results from the trastuzumab emtansine Phase III EMILIA trial conducted by Roche.
Obesity − as research in the past decade has shown − is first and foremost a brain disease. Researchers at Helmholtz Zentrum München, partners in the German Center for Diabetes Research, have now discovered a molecular switch that controls the function of satiety neurons and therefore body weight. The findings were published in the journal 'Nature Metabolism'.
› Verified 4 days ago
| Entity Name | Mary Hitchcock Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023092053 PECOS PAC ID: 4486561164 Enrollment ID: O20031126000258 |
News Archive
The FRS Company, a developer and distributor of FRS® Healthy Energy® products, announced today that it has received $23.1 million in its latest financing round led by Oak Investment Partners, LLC. Oak Investment Partners was an early investor in The FRS Company, and its continued support of FRS validates the company's aggressive business strategy for national and international expansion and explosive sales growth.
Despite technological advances, discrimination against consumers inhibited by disabilities or disadvantaged by personal circumstances remains a significant problem. Many people today find themselves excluded by mainstream, day-to-day services on which they rely, such as banks, utilities, telecoms, health services and local authority providers. Their vulnerability can be hidden, a consequence of personal trauma or a health condition, or temporary resulting from a job loss. These are complex issues for organizations to identify and respond to appropriately.
Stem cell biology takes another exciting leap forward as scientists report that normal tissue cells can be reprogrammed to exhibit many of the properties that are characteristic of embryonic stem cells, including the ability to give rise to multiple cell types and contribute to the germline.
ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced results from the trastuzumab emtansine Phase III EMILIA trial conducted by Roche.
Obesity − as research in the past decade has shown − is first and foremost a brain disease. Researchers at Helmholtz Zentrum München, partners in the German Center for Diabetes Research, have now discovered a molecular switch that controls the function of satiety neurons and therefore body weight. The findings were published in the journal 'Nature Metabolism'.
› Verified 4 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
The FRS Company, a developer and distributor of FRS® Healthy Energy® products, announced today that it has received $23.1 million in its latest financing round led by Oak Investment Partners, LLC. Oak Investment Partners was an early investor in The FRS Company, and its continued support of FRS validates the company's aggressive business strategy for national and international expansion and explosive sales growth.
Despite technological advances, discrimination against consumers inhibited by disabilities or disadvantaged by personal circumstances remains a significant problem. Many people today find themselves excluded by mainstream, day-to-day services on which they rely, such as banks, utilities, telecoms, health services and local authority providers. Their vulnerability can be hidden, a consequence of personal trauma or a health condition, or temporary resulting from a job loss. These are complex issues for organizations to identify and respond to appropriately.
Stem cell biology takes another exciting leap forward as scientists report that normal tissue cells can be reprogrammed to exhibit many of the properties that are characteristic of embryonic stem cells, including the ability to give rise to multiple cell types and contribute to the germline.
ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced results from the trastuzumab emtansine Phase III EMILIA trial conducted by Roche.
Obesity − as research in the past decade has shown − is first and foremost a brain disease. Researchers at Helmholtz Zentrum München, partners in the German Center for Diabetes Research, have now discovered a molecular switch that controls the function of satiety neurons and therefore body weight. The findings were published in the journal 'Nature Metabolism'.
› Verified 4 days ago
| Entity Name | Cottage Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528162799 PECOS PAC ID: 1951219617 Enrollment ID: O20050509000013 |
News Archive
The FRS Company, a developer and distributor of FRS® Healthy Energy® products, announced today that it has received $23.1 million in its latest financing round led by Oak Investment Partners, LLC. Oak Investment Partners was an early investor in The FRS Company, and its continued support of FRS validates the company's aggressive business strategy for national and international expansion and explosive sales growth.
Despite technological advances, discrimination against consumers inhibited by disabilities or disadvantaged by personal circumstances remains a significant problem. Many people today find themselves excluded by mainstream, day-to-day services on which they rely, such as banks, utilities, telecoms, health services and local authority providers. Their vulnerability can be hidden, a consequence of personal trauma or a health condition, or temporary resulting from a job loss. These are complex issues for organizations to identify and respond to appropriately.
Stem cell biology takes another exciting leap forward as scientists report that normal tissue cells can be reprogrammed to exhibit many of the properties that are characteristic of embryonic stem cells, including the ability to give rise to multiple cell types and contribute to the germline.
ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced results from the trastuzumab emtansine Phase III EMILIA trial conducted by Roche.
Obesity − as research in the past decade has shown − is first and foremost a brain disease. Researchers at Helmholtz Zentrum München, partners in the German Center for Diabetes Research, have now discovered a molecular switch that controls the function of satiety neurons and therefore body weight. The findings were published in the journal 'Nature Metabolism'.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alexei Viazmenski, MD 1 Medical Center Dr, Lebanon, NH 03756-1000 Ph: (603) 650-5000 | Alexei Viazmenski, MD 1 Medical Center Dr, Lebanon, NH 03756-1000 Ph: (603) 650-5000 |
News Archive
The FRS Company, a developer and distributor of FRS® Healthy Energy® products, announced today that it has received $23.1 million in its latest financing round led by Oak Investment Partners, LLC. Oak Investment Partners was an early investor in The FRS Company, and its continued support of FRS validates the company's aggressive business strategy for national and international expansion and explosive sales growth.
Despite technological advances, discrimination against consumers inhibited by disabilities or disadvantaged by personal circumstances remains a significant problem. Many people today find themselves excluded by mainstream, day-to-day services on which they rely, such as banks, utilities, telecoms, health services and local authority providers. Their vulnerability can be hidden, a consequence of personal trauma or a health condition, or temporary resulting from a job loss. These are complex issues for organizations to identify and respond to appropriately.
Stem cell biology takes another exciting leap forward as scientists report that normal tissue cells can be reprogrammed to exhibit many of the properties that are characteristic of embryonic stem cells, including the ability to give rise to multiple cell types and contribute to the germline.
ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced results from the trastuzumab emtansine Phase III EMILIA trial conducted by Roche.
Obesity − as research in the past decade has shown − is first and foremost a brain disease. Researchers at Helmholtz Zentrum München, partners in the German Center for Diabetes Research, have now discovered a molecular switch that controls the function of satiety neurons and therefore body weight. The findings were published in the journal 'Nature Metabolism'.
› Verified 4 days ago
Thomas Ray Burdick, Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5000 | |
William B. Zucconi, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5000 | |
Dr. Thomas Francis Delaney, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-6600 | |
Dr. Jessica Margaret Sin, M.D., PH.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Dr, Lebanon, NH 03756 Phone: 603-650-7650 | |
Dr. Harlan G Herr, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-7650 | |
Matthew E Maeder, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-4371 | |
Dr. Judith Austin-strohbehn, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Department Of Radiology, Lebanon, NH 03756 Phone: 603-650-4477 Fax: 603-650-5455 |